Laura Esserman, MD, MBA, an internationally recognized breast surgeon, breast oncology specialist, and visionary in personalized medicine, is revolutionizing breast cancer screening and treatment throughout our nation today.
As a Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and the Director of the UCSF Carol Franc Buck Breast Care Center, Dr. Esserman's breast cancer work spans a spectrum from basic science to public policy issues and the impact of both on the delivery of clinical care. She is a provocative thought leader calling attention to and finding solutions for over-diagnosis and over-treatment of breast cancer, especially of DCIS.
Since 2002, Dr. Esserman has led the I-SPY TRIALS, a ground-breaking national public-private collaboration among NCI, FDA, more than 20 cancer research centers, and major pharma, biotech companies, and the not for profit sponsor, Quantum Leap Healthcare Collaborative. This trial model, which has now become an international model for translational research, designed to shave several years and tens of millions of dollars off the drug development process. The trial paradigm is now being developed for use in other disease domains, and she recently got FDA approval for an I-SPY Covid trial, designed to rapidly screen and confirm high impact treatments to reduce mortality and time on ventilators.
Additionally, Dr. Esserman led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. As part of the network, she has spearheaded the development of the WISDOM study to learn how to improve breast cancer screening by testing and comparing the safety and efficacy of a personalized screening strategy informed by each woman's breast cancer risk and preferences against the standard of annual screening.
Dr. Esserman is a passionate and persistent advocate for her patients. She is keenly aware that many of her patients don't have 10 years to wait for the right treatment options. Her work is dedicated to accelerating the development of targeted, effective prevention and treatment options that can make a difference at the time when they are needed the most. Through these efforts, Dr. Esserman is helping to reshape the healthcare system, and changing it from a general population approach to a personalized and patient-centered care model.
Dr. Esserman has published more than 300 articles in peer-reviewed journals, and is regularly consulted by prestigious scientific, business, and consumer media including The New York Times, Wall Street Journal, Los Angeles Times, Health Magazine, Prevention Magazine, The Newshour, ABC World News, the NBC Nightly News, the CBS Evening News, and NPR's Science Friday.
Dr. Esserman was included as one of TIME Magazine's 100 Most Influential People of 2016, and was the recipient of the 2016 Stanford Business School Ernest C. Arbuckle Award and the 2016 Personalized Medicine World Conference Pioneer and Luminary Award. The San Francisco Business Times honored her with the Most Influential Women in Business Awards for 2018, and she also received the 2018 Giant of Cancer Care® in Cancer Diagnostics award.